Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ImmunoCellular Therapeutics Ltd.

www.imuc.com

Latest From Teikoku Seiyaku Co. Ltd.

FTC Focus On Pay-For-Delay Deals Continues; Endo Agrees To 10-Year Abstention

In addition to settling with Endo, FTC refiles charges against Watson (now Teva), Allergan and Impax involving Lidoderm and Opana ER patent litigation settlements.

BioPharmaceutical Policy & Regulation

FTC v. Endo: Does No-Authorized Generic Agreement Meet Supreme Court Pay-For-Delay Test?

FTC alleges Endo's Opana ER patent settlement with Impax gave it time to introduce a reformulated product; agency also challenges side deal on Parkinson's disease drug and Endo's Lidoderm settlement with Watson.

BioPharmaceutical Legal Issues

Chuikyo Releases New Round Of Price Listings In Japan

BMS’ Orencia, Sanofi’s Lyxumia, Chugai’s Perjeta and others are now cleared for the market after receiving National Health Insurance price listings.

BioPharmaceutical Japan

Japan pricing sets stage for first global launches of glycopyrronium and anagliptin

Two new products are being prepared for their first launches worldwide, in Japan, following the granting of official reimbursement prices for a batch of products by the country's ministry of health, labour and welfare.

Gastrointestinal Metabolic Disorders
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Optical Molecular Imaging Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • ImmunoCellular Therapeutics Ltd.
  • Senior Management
  • Andrew Gengos, Pres. & CEO
    David Fractor, VP, Fin.
    John S Yu, MD, CSO
    Steven Swanson, PhD, SVP, Research
  • Contact Info
  • ImmunoCellular Therapeutics Ltd.
    Phone: (818) 264-2300
    23622 Calabasas Rd.
    Ste. 300
    Calabasas, CA 91302
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register